RT Journal Article SR Electronic T1 Metabolomic changes associated with frontotemporal lobar degeneration syndromes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.10.20021758 DO 10.1101/2020.02.10.20021758 A1 Alexander G. Murley A1 P Simon Jones A1 Ian Coyle Gilchrist A1 Lucy Bowns A1 Julie Wiggins A1 Kamen A. Tsvetanov A1 James B. Rowe YR 2020 UL http://medrxiv.org/content/early/2020/02/12/2020.02.10.20021758.abstract AB Objective Widespread metabolic changes are seen in neurodegenerative disease and could be used as biomarkers for diagnosis and disease monitoring. They may also reveal disease mechanisms that could be a target for therapy. In this study we looked for blood-based biomarkers in syndromes associated with frontotemporal lobar degeneration.Methods Plasma metabolomic profiles were measured from 134 patients with frontotemporal lobar degeneration (behavioural variant frontotemporal dementia n=30, non fluent variant primary progressive aphasia n=26, progressive supranuclear palsy n=45, corticobasal syndrome n=33) and 32 healthy controls.Results Forty-nine of 842 metabolites were significantly altered in frontotemporal lobar degeneration (after false-discovery rate correction for multiple comparisons). These were distributed across a wide range of metabolic pathways including amino acids, energy and carbohydrate, cofactor and vitamin, lipid and nucleotide pathways. The metabolomic profile supported classification between frontotemporal lobar degeneration and controls with high accuracy (88.1-96.6%) while classification accuracy was lower between the frontotemporal lobar degeneration syndromes (72.1-83.3%). One metabolic profile, comprising a range of different pathways, was consistently identified as a feature of each disease versus controls: the degree to which a patient expressed this metabolomic profile was associated with their subsequent survival (hazard ratio 0.74 [0.59-0.93], p = 0.0018).Conclusions The metabolic changes in FTLD are promising diagnostic and prognostic biomarkers. Further work is required to replicate these findings, examine longitudinal change, and test their utility in differentiating between FTLD syndromes that are pathologically distinct but phenotypically similar.Competing Interest StatementAlexander Murley, P Simon Jones, Ian Coyle Gilchrist, Lucy Bowns, Julie Wiggins and Kamen A. Tsvetanov report no disclosures. James B Rowe reports consultancy for Asceneuron and UCB; research grants from Janssen, AZ-Medimmune, Lilly; and serves as editor for Brain.Funding StatementThis work was supported by the Holt Fellowship, the Wellcome Trust (103838), the Cambridge Centre for Parkinson-plus, the British Academy (PF160048) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (146281).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data are available on reasonable request for academic purposes.